7 completed, 5 terminated, 3 recruiting, 3 unknown. 22 Phase 1, 7 Phase 2.
Follow Advanced Malignant Neoplasm: new trials by email Literature Review of Advanced Malignant Neoplasm trials Research Report on Advanced Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors IAP0971 - Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | SUNHO（China）BioPharmaceutical CO., Ltd. | 78 | 2024-12-31 | 2025-01-15 |
| A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors QLF31907, Irinotecan, Docetaxel - Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2024-06-15 | 2024-05-01 |
| TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. TQB2928 injection, Penpulimab - Advanced Malignant Neoplasm | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 3 | 2024-05-24 | 2024-08-06 |
| A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer TQB3006 tablets - Advanced Malignant Neoplasm | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 27 | 2024-04-25 | 2025-05-22 |
| A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets TQB3909 tablets, Itraconazole capsule, Rifampicin capsule - Advanced Malignant Neoplasm | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 40 | 2023-12-01 | 2023-12-12 |
| A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer TQB3015 tablets - Advanced Malignant Neoplasm | Phase 1 | Withdrawn | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-12-01 | 2023-12-29 | |
| A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies AUR106 - Relapse, Advanced Malignant Neoplasm | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 21 | 2023-08-26 | 2026-04-17 |
| A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor TQB3912 tablets - Advanced Malignant Neoplasm | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 36 | 2023-08-16 | 2025-08-11 |
| Clinical Trial Evaluating the Safety of the TQB2103 for Injection TQB2103 for injection - Advanced Malignant Neoplasm | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 71 | 2023-07-04 | 2023-07-10 |
| A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm Intravenous Infusion - Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Unknown | Mabwell (Shanghai) Bioscience Co., Ltd. | 272 | 2021-09-27 | 2022-05-09 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II - Advanced Malignant Neoplasm, Breast Cancer | Phase 1 / Phase 2 | Recruiting | AtlasMedx, Incorporated | 122 | 2020-08-12 | 2025-05-01 |
| Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Bevacizumab, Fluorouracil, Leucovorin - Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver | Phase 1 | Terminated | M.D. Anderson Cancer Center | 38 | 2020-06-23 | 2026-07-27 |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Ziftomenib, Midazolam, Itraconazole - Advanced Malignant Neoplasm, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | Kura Oncology, Inc. | 263 | 2019-09-12 | 2026-05-13 |
| First-in-Human Study of KO-947 in Non-Hematological Malignancies KO-947 - Advanced Malignant Neoplasm | Phase 1 | Terminated | Kura Oncology, Inc. | 61 | 2017-04-06 | 2021-09-20 |
| Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Vimseltinib - Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 120 | 2017-02-16 | 2026-06-25 |
| Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Muscadine Grape Skin Extract, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | Wake Forest University Health Sciences | 24 | 2016-03-01 | 2023-06-05 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease | Phase 1 | Terminated | M.D. Anderson Cancer Center | 154 | 2012-10-16 | 2026-05-15 |
| Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers Anakinra, Denosumab, Everolimus - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 57 | 2012-06-19 | 2021-02-25 |
| Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 123 | 2012-05-14 | 2026-08-28 |
Showing 20 of 22. Sign in to see all of them.
Neoplasm Metastasis (6) · Neoplasms (6) · Recurrence (5) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Transitional Cell (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Castleman Disease (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Disease Progression (1) · Endocrine Gland Neoplasms (1) · Endometrial Neoplasms (1) · Erdheim-Chester Disease (1)
Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Disease Attributes (6) · Neoplasms (6) · Neoplasms by Site (6) · Neoplastic Processes (6) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Neoplasms by Histologic Type (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Breast Diseases (3) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3)
Bevacizumab (2) · Disulfides (2) · Everolimus (2) · Immunoglobulin G (2) · Itraconazole (2) · Sirolimus (2) · Sorafenib (2) · temsirolimus (2) · Cetuximab (1) · Clinical Trials, Phase I as Topic (1) · Clinical Trials, Phase II as Topic (1) · Crizotinib (1) · Denosumab (1) · Docetaxel (1) · Doxorubicin (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (5) · M.D. Anderson Cancer Center (5) · Kura Oncology, Inc. (2) · AtlasMedx, Incorporated (1) · Aurigene Discovery Technologies Limited (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · Deciphera Pharmaceuticals, LLC (1) · Mabwell (Shanghai) Bioscience Co., Ltd. (1) · National Cancer Institute (NCI) (1) · PMV Pharmaceuticals, Inc (1) · Qilu Pharmaceutical Co., Ltd. (1) · SUNHO（China）BioPharmaceutical CO., Ltd. (1) · Wake Forest University Health Sciences (1)
United States (12) · China (8) · Spain (4) · France (3) · Italy (3) · Australia (2) · Canada (2) · Germany (2) · United Kingdom (2) · Belgium (1) · India (1) · Netherlands (1) · Poland (1) · Singapore (1) · South Korea (1)
Filip Janku (2) · Akhil Kumar, MD (1) · David Hong (1) · Heidi Klepin (1) · Jian Zhang, Professor (1) · Maitreyi Sharma, MD (1) · Marc Fellous, MD (1) · Pamela Munster, MD (1) · Sarina A Piha-Paul (1) · Sarina Piha-Paul, MD (1) · Siqing Fu (1)
PMID 23676418, PMID 25982012, PMID 33741715, PMID 33867481, PMID 34267079, PMID 37311055, PMID 39362248, PMID 40543428, PMID 40932470, PMID 40997296, PMID 41389341, PMID 41740031
P30CA016672 (3), P30CA012197 (1), U01CA062461 (1)